<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278978</url>
  </required_header>
  <id_info>
    <org_study_id>201306022MIPB</org_study_id>
    <nct_id>NCT02278978</nct_id>
  </id_info>
  <brief_title>BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma</brief_title>
  <official_title>A Phase II Trial of BIBF1120 in Patients With Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and Renal Pelvis and Who Have Failed Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIBF1120 in patients with advanced FGFR3 mutated, FGFR3 overexpressed, or FGFR3 wild type
      urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have
      failed platinum-based chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate assessed by RECEST version 1.1</measure>
    <time_frame>2 months</time_frame>
    <description>To define the response rate of BIBF1120 in patients with advanced FGFR3-mutated,overexpressed,wild type UC and who have failed platinum-based chemotherapy.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>FGFR3 mutated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIBF 1120 in patients with advanced FGFR3 mutated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FGFR3 overexpressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIBF 1120 in patients with advanced FGFR3 overexpressed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FGFR3 wild type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIBF 1120 in patients with advanced FGFR3 wild type</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF1120</intervention_name>
    <description>BIBF1120 200 mg two times per day orally</description>
    <arm_group_label>FGFR3 mutated</arm_group_label>
    <arm_group_label>FGFR3 overexpressed</arm_group_label>
    <arm_group_label>FGFR3 wild type</arm_group_label>
    <other_name>Nintedanib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  KPS 60%

          -  Histological confirmation of urothelial carcinoma , with metastatic disease

          -  Measurable disease

          -  Previously treated with platinum-based chemotherapy administered

        Exclusion Criteria:

          -  Radiographic evidence of cavitary or necrotic tumours

          -  Active brain metastasis.Leptomeningeal metastasis

          -  Chemotherapy, radiotherapy, targeted therapy with monoclonal antibodies or small
             tyrosine kinase inhibitors

          -  Grade 1 treatment-related toxicity from previous chemotherapy, radiotherapy, or
             targeted therapy

          -  Prior treatment with BIBF 1120 or other VEGFR inhibitors

          -  Significant cardiovascular diseases:

          -  Pericardial effusion

          -  Significant bleeding or thrombosis

          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of
             the study drug

          -  Major injuries within the past 10 days with incomplete wound healing and/or planned
             surgery during the on-treatment study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia-Chi Lin, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chia-Chi Lin</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>May 10, 2015</last_update_submitted>
  <last_update_submitted_qc>May 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urothelial carcinoma</keyword>
  <keyword>BIBF1120</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

